Home
/
Treatment
/
RNA, [P-deoxy-P-(dimethylamino)] (2′,3′-dideoxy-2′,3′-imino-2′,3′-seco) (2’a?5′)(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G),...

RNA, [P-deoxy-P-(dimethylamino)] (2′,3′-dideoxy-2′,3′-imino-2′,3′-seco) (2’a?5′)(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy] ethoxy]carbonyl]-1-piperazinyl]-N,Ndimethylaminophosphonamidate

	RNA, [P-deoxy-P-(dimethylamino)] (2′,3′-dideoxy-2′,3′-imino-2′,3′-seco) (2’a?5′)(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy] ethoxy]carbonyl]-1-piperazinyl]-N,Ndimethylaminophosphonamidate
Trade Name
Orphan Indication	Duchenne muscular dystrophy
EU Market Approval	EU
EU Designation Date	2008-12-03 00:00:00
Sponsor	AVI BioPharma International Ltd

Related Access Program